Abstract
The capsular polysaccharide (CPS) is essential for Streptococcus pneumoniae virulence. Its synthesis requires multiple enzymes, and defects that block completion of the pathway can be lethal in the absence of secondary suppressor mutations. In this study, we examined the functions of three capsular glycosyltransferases (Cps2F, Cps2G, and Cps2I) involved in serotype 2 CPS synthesis, whose deletions select for secondary mutations. We demonstrate that Cps2F is a rhamnosyltransferase that catalyzes addition of the third and fourth sugars in the capsule repeat unit, while Cps2G adds the fifth sugar (glucose). Addition of the terminal residue (glucuronic acid) could not be detected; however, activities of the other glycosyltransferases together with bioinformatic analyses suggest that this step is mediated by Cps2I. Most of the secondary suppressor mutations resulting from loss of these enzymes occur in cps2E, the gene encoding the initiating glycosyltransferase. Examination of the 69 S. pneumoniae serotypes containing Cps2E homologues yielded a consensus amino acid sequence for this protein and demonstrated that there is a highly significant association between the residues that are 100% conserved and those altered by suppressor mutations. Cps2E contains an extracytoplasmic loop whose function is unknown. Among our collection of mutants, six contained missense mutations affecting amino acids in the extracytoplasmic loop. These residues are highly conserved among S. pneumoniae Cps2E homologues, and mutations therein severely reduced CPS synthesis and Cps2E activity. The critical functions of these amino acids suggest a role for the Cps2E extracytoplasmic loop in initiation, and possibly regulation, of capsule synthesis.
INTRODUCTION
Streptococcus pneumoniae (the pneumococcus) is an extracellular bacterial pathogen that produces a protective surface structure known as the capsular polysaccharide (CPS). The CPS is an essential component for virulence, influencing both nasopharyngeal colonization and systemic infection (1–8). CPS is also an immunodominant surface antigen that serves as the basis for S. pneumoniae serological typing and protective vaccines (3, 9–14). Over 90 CPS serotypes have been identified; all but 2 utilize the Wzy-dependent pathway to synthesize CPS, while the remaining serotypes (serotypes 3 and 37) utilize the synthase-dependent pathway (15–18). This study focused on the Wzy-dependent pathway, which was first identified as a mechanism of synthesis for lipopolysaccharide O antigen in Gram-negative bacteria (19–21) but is the principal mechanism for CPS synthesis in Gram-positive bacteria (18).
In the Wzy-dependent pathway, the capsule repeat unit is synthesized on the membrane acceptor undecaprenyl phosphate (Und-P) by multiple glycosyltransferases. Once completed, the repeat unit is transported across the cytoplasmic membrane by a Wzx translocase and polymerized by a Wzy polymerase (Fig. 1). As a model for studying the Wzy-dependent pathway in S. pneumoniae, our laboratory uses capsule serotype 2, which contains a hexasaccharide repeat unit comprised of glucose (Glc), rhamnose (Rha), and glucuronic acid (GlcUA) residues (22) that is polymerized to at least 1,000 to 2,000 repeat units, based on the molecular sizes of isolated polymers used in vaccine preparations (23) (Fig. 1). We previously identified and characterized the first two glycosyltransferases involved in synthesizing the serotype 2 repeat unit: the glucose-1-phosphate (Glc-1-P) transferase Cps2E, which initiates synthesis (24), and the β1-4 rhamnosyltransferase Cps2T, which catalyzes the second and committed step (25).
There are a limited number of publications characterizing pneumococcal glycosyltransferases involved in Wzy-dependent capsule synthesis. In S. pneumoniae, homologues of the initiating glycosyltransferase CpsE (also known as WchA) are present in at least 69 serotypes (15). The glycosyltransferase activities of these enzymes have been established, with enzyme functions demonstrated in serotypes 2, 8, 9v, and 14 (24, 26–28). CpsE is a member of the polyprenyl-phosphate hexose-1-phosphate transferase (PHPT) family (20), in which the Salmonella enterica galactose-1-phosphate transferase WbaP serves as the prototypic enzyme (29–31). Three distinct regions are present in PHPT enzymes: the N terminus, which in Cps2E contains 4 membrane-spanning domains; a central, extracytoplasmic loop; and a C-terminal cytoplasmic tail following a membrane-spanning domain (31–34). Sugar transfer is catalyzed by residues in the cytoplasmic tail, as independent studies have shown this region to be sufficient for glycosyltransferase activity (27, 31, 32, 35). The N-terminal region is suggested to be required for protein insertion or stability in the membrane (31). The function of the extracytoplasmic loop is less clear, but recent studies have suggested a role in modulation of chain length distribution (31).
Three other genes in the cps2 locus—cps2F, cps2G, and cps2I—are predicted to encode the glycosyltransferases required for completion of the repeat unit (Fig. 1) (25, 36, 37), but biochemical evidence supporting their functions is lacking. In previous reports, we demonstrated that deletion of any one of these genes, or of the UDP-glucose dehydrogenase encoded by cps2K, the Wzx translocase (cps2J), or the Wzy polymerase (cps2H), was lethal in the absence of secondary mutations, the majority of which mapped to cps2E (25, 34). Each of the primary mutations affected a point in the pathway past the committed step (Cps2T-catalyzed addition of the first Rha). The lethality was attributed to either destabilization of the membrane by the buildup of incomplete repeat units or sequestration of Und-P in the capsule pathway and away from essential pathways such as peptidoglycan synthesis. Other reports have described similar suppressor mutations, some of which occurred in the initiating glycosyltransferase, when primary mutations blocked the completion of polysaccharide pathways in Pseudomonas aeruginosa lipopolysaccharide (LPS) Wzx flippase mutants (38), Xanthomonas campestris xanthan gum mutants (39), and Salmonella enterica serovar Typhimurium LPS mutants that failed to polymerize O-antigen subunits (30). To date, we have obtained over 30 unique suppressor mutations in cps2E that are distributed throughout the C-terminal cytoplasmic tail and the central extracytoplasmic loop (25, 34). Suppressor mutations mapping to the C-terminal region can be interpreted as a direct inhibition of Glc-1-P transferase activity. Suppressor mutations that map to the extracytoplasmic loop, however, are more difficult to interpret but must have a function in limiting the accumulation of incomplete repeat units.
In this report, we provide biochemical evidence for the previously uncharacterized glycosyltransferases Cps2F and Cps2G that, together with bioinformatic analyses, completes the transferase specificities for the type 2 CPS repeat unit of S. pneumoniae. We also further characterize our novel collection of secondary mutations in cps2E and demonstrate that residues in the extracytoplasmic loop are critical for repeat unit initiation.
MATERIALS AND METHODS
Bacterial strains and growth conditions.
S. pneumoniae strains (Table 1) were grown at 37°C in THY (Todd-Hewitt broth supplemented with 0.5% yeast extract) or on blood agar plates (BBL [Difco] or blood agar base [Becton and Dickinson] containing 3% defibrinated sheep blood [Colorado Serum Company]). Broth cultures were grown statically at 37°C. Plate cultures were incubated at 37°C in a candle jar. Escherichia coli strains (Table 1) were grown at 37°C in L broth (1% tryptone, 0.5% yeast extract, 0.5% NaCl, and 0.1% glucose) with shaking or on L agar plates (15 g of agar/liter of L broth). Media were supplemented with the following antibiotics as appropriate: ampicillin (Ap; 100 μg/ml), erythromycin (Em; 15 μg/ml for E. coli DB11 and 0.3 μg/ml for S. pneumoniae), and kanamycin (Km; 250 μg/ml).
Table 1.
Strain or plasmid | Propertiesa | Reference or source |
---|---|---|
S. pneumoniae | ||
BX547 | D39 Δcps2K Cpsr; cps2E5544 G→T (D167Y) Kmr | 34 |
BX552 | D39 Δcps2H Cps− cps2E5539 C→T (L200F); Kmr (in the original publication, this mutant was incorrectly identified as L199F) | 34 |
BX605 | D39 Δcps2K Cpsr cps2E5632T→G (V196G) Kmr | 34 |
BX612 | D39 Δcps2K Cpsr cps2E5539T→G (V165G) Kmr | 34 |
D39 | Type 2 parent strain; Cps+ | 57 |
DJ916 | D39 Δcps2F Cps− cps2E5718 A→G (H258R) Kmr | 25 |
DJ918 | D39 Δcps2G Cpsr cps2E6059G→C (M338I) Kmr | 25 |
DJ919 | D39 Δcps2G Cpsr cps2E6964C→A (R307S) Kmr | 25 |
DJ921 | D39 Δcps2G Cpsr cps2E5529G→T (A162S) Kmr | 25 |
JK901 | pJK101 X D39; Cps−; aphA-3 inserted into cps2E; Kmr | This study |
JK903 | pBX146 X JK901; cps2E repair; Cps+ | This study |
JK906 | pDJ238 X JK901; cps2E5632T→G (V196G) Cpsr | This study |
JK907 | pDJ241 X JK901; cps2E5718A→G (H258R) Cpsr | This study |
KA1522 | D39 Δcps2E Cps− | 24 |
WU2 | Type 3 parent strain; Cps+ | 58 |
E. coli | ||
BL21-AI | F− ompT hsdSB(rB− mB−) gal dcm araB::T7 RNAP-tetA | Invitrogen |
DB11 | met thi gal hasdR nal rif; plasmid-cured derivative of V854 from reference 59 | 59 |
DH5α | F− Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK− mK+) phoA supE44 λ− thi-1 gyrA96 relA1 | Invitrogen |
DJ005 | BL21-AI expressing Cps2I; Apr | 25 |
DJ009 | BL21-AI expressing Cps2T; Apr | 25 |
DJ011 | BL21-AI expressing Cps2G; Apr | 25 |
DJ204 | BL21-AI expressing Cps2F, replaced GTG start with ATG; Apr | 25 |
DJ238 | DB11 (pDJ248); used to transform cps2E5718A→G (H258R) | |
DJ241 | DB11 (pDJ241); used to transform cps2E5632T→G (V196G) | |
DJ252 | BL21-AI (pDJ252) expressing Cps2EH258R; Apr | This study |
DJ253 | BL21-AI (pDJ253) expressing Cps2EA162S; Apr | This study |
DJ254 | BL21-AI (pDJ254) expressing Cps2ED167Y; Apr | This study |
DJ269 | BL21-AI (pDJ269) expressing Cps2EL200F; Apr | This study |
DJ270 | BL21-AI (pDJ269) expressing Cps2EV196G; Apr | This study |
DJ271 | DH5α (pDJ271); aphA-containing clone; Kmr | This study |
JK101 | DB11 (pJK101); contains aphA-3-disrupted cps2E; Kmr | This study |
KJ4152 | BL21-AI (pKJ4152) expressing full-length Cps2E; Apr | 25 |
RC124 | BL21-AI (pET20b) vector control; Apr | 24 |
Plasmids | ||
pBX146 | pJY4164/cps2E; amplified from D39 using primer pair cps2-D3/cps2-T1; contains full-length parental cps2E. This plasmid is the same as the published pBX145. | 34 |
pET20b | Protein expression vector; Apr | Novagen |
pDJ238 | pBX146/cps2E5718A→G (H258R) amplified from DJ916 using primers E8/E11b | This study |
pDJ241 | pBX146/cps2E5632T→G (V196G) amplified from BX605 using primers E8/E11b | This study |
pDJ252 | pET-20b/cps2E5718 A→G (H258R) amplified from DJ916 using primers E8/E11b | This study |
pDJ253 | pET-20b/cps2E5529G→T (A162S) amplified from DJ921 using primers E8/E11b | This study |
pDJ254 | pET-20b/cps2E5544 G→T (D167Y) amplified from BX547 using primers E8/E11b | This study |
pDJ269 | pET-20b/cps2E5539 C→T (L200F) amplified from BX552 using primers E8/E11b | This study |
pDJ270 | pET-20b/cps2E5632 T→G (V196G) amplified from BX605 using primers E8/E11b | This study |
pDJ271 | pGEM-T Easy/aphA-3-containing fragment amplified using primer pair DJ-03/DJ-04 | This study |
pJK101 | pBX146/aphA-3 from BstBI-digested product of pDJ271 | This study |
pJY4164 | S. pneumoniae suicide vector; Emr | 41 |
pKJ4152 | pET-20b/cps2E amplified from S. pneumoniae D39 using primers E8/E11b | 25 |
cps2E superscripts indicate locations of mutations based on GenBank accession no. AF026471. Amino acid changes are indicated in parentheses. Cpsr, reduced capsule levels; →, nucleotide change; Apr, ampicillin resistant.
Primers are described in Materials and Methods.
Cloning of glycosyltransferase mutant enzymes.
Sequences for cps2E with the mutations cps2E5718A→G (H258R), cps2E5529G→T (A162S), cps2E5544G→T (D167Y), cps2E5539C→T (L200F), and cps2E5632T→G (V196G) were PCR amplified from the chromosomal DNA of S. pneumoniae strains DJ916, DJ921, BX547, BX552, and BX605, respectively. The primer pair used in PCRs was E8 (CATATGAATGGAAAAACAGTAAAGTC) and E11 (CTCGAGCTACTTCGCTCCATCTCTC), which amplifies a 1.2-kb fragment containing the full-length cps2E (24). PCR products were cloned into pET-20b and transformed into chemically competent E. coli BL21-AI. The resulting strains DJ252 (Cps2EH258R), DJ253 (Cps2EA162S), DJ254 (Cps2ED167Y), DJ269 (Cps2EL200F), and DJ270 (Cps2EV196G) were used for expression of proteins for glycosyltransferase assays, as described below.
Introduction of cps2E point mutations into S. pneumoniae D39.
To facilitate identification of isolates transformed with cps2E point mutations, allelic exchange was used to insert a kanamycin resistance-encoding (Kmr) cassette (aphA-3) into the native cps2E. The aphA-3 gene was PCR amplified from the pneumococcal shuttle vector pSF151 (40) using primer pair DJ-03/DJ-04 and cloned into pGEM-T Easy cloning vector, resulting in pDJ271 (all plasmids were isolated and maintained in E. coli DH5α or DB11). Following digestion of pDJ271 with BstBI, the released aphA-3-containing fragment was ligated into BstBI-digested pBX146. The latter plasmid contains the full-length cps2E and partial upstream and downstream sequences (cps2D and cps2T, respectively) cloned into the pneumococcal suicide vector pJY4164, which encodes Em resistance (Emr) (41). BstBI cuts pBX146 at a single site within cps2E, allowing introduction of the aphA-3 fragment. The resulting construct, pJK101, was used to transform competent D39 (42). Kmr isolates were demonstrated to be CPS negative and Em sensitive (Ems). The latter property indicates that Kmr was the result of allelic exchange and not single crossover resulting in integration of the entire clone into the recipient chromosome. The Kmr isolate JK901 was used in subsequent studies.
Constructs containing the cps2E suppressor mutations encoding V196G and H258R were generated by PCR amplification of chromosomal DNA from strains DJ916 and BX605, respectively, using primer pair E8/E11 (primer sequences listed above) to amplify the full-length cps2E. The fragments were cloned into the pGEM-T Easy cloning vector, and the subsequent clone was then digested with MscI/BlpI. The released fragments were ligated to MscI/BlpI-digested pBX146. Digestion with MscI/BlpI releases a 751-bp internal fragment of cps2E that encompasses the sites of the mutations. The mutant plasmids resulting from these ligations (pDJ238, V196A, and pDJ241, H258R), along with the parent pBX146, were transformed into competent JK901 (cps2E::aph-3 Kmr), and reaction mixtures were plated on blood agar in the absence of antibiotic selection. Individual colonies were screened for Km sensitivity by patching on blood agar with and without Km. Sensitive isolates were tested for Em sensitivity to confirm that the entire plasmid had not integrated into the chromosome. The resulting strains were confirmed to have only the expected mutations (JK906, V196, and JK907, H258) or the parental sequence (JK903) by DNA sequencing of cps2E. The frequencies of obtaining these mutants were 0.3% (13/4,000) for JK906, 0.1% (6/6,000) for JK907, and 0.7% (27/4,000) for JK903. Sequencing was performed by the UAB Genomics Core Facility of the Heflin Center for Genomic Science.
Glycosyltransferase expression and membrane isolation.
The previously constructed E. coli strains expressing Cps2E (KJ4152), Cps2T (DJ009), Cps2F (DJ204), Cps2G (DJ011), and Cps2I (DJ005) were cultured and processed for membrane isolation as previously described (25). None of these constructs or those for other glycosyltransferases contained tags. For expression, 250-ml cultures were grown with the appropriate antibiotic selection to mid-exponential phase (cell density of approximately 4.5 × 108 CFU/ml) and then induced with 0.2% arabinose for 30 min (Cps2E and derivatives) or 4 h (all others). Cultures were centrifuged, and the cells were washed and lysed as previously described (25), followed by centrifugation at 100,000 × g to collect membranes. The final membrane pellet was suspended in 500 μl Tris-acetate (100 mM, pH 7.5) containing 10% glycerol and 1 mM dithiothreitol (DTT; buffer A) and stored at −80°C. Frozen membranes were thawed and vigorously vortexed, and the homogenized solution was used to determine total membrane protein concentrations using the Bradford Bio-Rad protein dye assay. Replicate samples (at least duplicate) were assayed. Membrane samples from the parent and mutant strains demonstrated similar levels of a non-capsule-related protein, indicating homogeneity of the solutions (see Results).
S. pneumoniae membranes were isolated based on previously described procedures (43, 44). Fifty-milliliter cultures were grown at 37°C in THY to a density of 3 × 108 CFU/ml. Cultures were centrifuged at 10,000 × g for 20 min. The cells were washed once in 50 ml of phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 5.4 mM Na2HPO4·7H2O, 1.8 mM KH2PO4 [pH 7.4]) and then suspended in 500 μl of protoplast buffer (20% sucrose, 50 mM Mg2SO4, 50 mM Tris-HCl [pH 7.4]). Samples were incubated overnight at room temperature with gentle rotation (the S. pneumoniae autolysin LytA is active under these conditions [44]). Protoplast formation was confirmed using phase-contrast light microscopy. The protoplasts were centrifuged at 16,000 × g for 10 min and washed once in 500 μl of protoplast buffer. Protoplasts were osmotically lysed by suspension in 1 ml of sterile water containing 10 mM EDTA, 1 mM DTT, and 1 mM phenylmethanesulfonyl fluoride, with incubation at room temperature for 30 min. Lysis was confirmed by light microscopy. Lysed cells were centrifuged at 16,000 or 100,000 × g (with equivalent results) for 20 min. The membrane-containing pellets were washed once in 1 ml of buffer A and suspended in 100 μl of buffer A. Total membrane protein concentrations were quantified using the Bradford Bio-Rad protein dye assay, as described above.
Synthesis, purification, and quantification of dTDP-Rha.
dTDP-Rha was synthesized in two steps essentially as previously described (25), with minor modifications to enzyme concentration and incubation time. Briefly, dTDP-Glc was synthesized in a 350-μl reaction mixture containing 50 mM HEPES (pH 7.6), 30 mM MgCl2, 3.4 mM dTTP, 3.4 mM Glc-1-P, 2 U of inorganic pyrophosphatase, and 2 μM Cps2L. After incubation for 90 min at 37°C, the proteins were removed by filtration using Amicon Ultra 10-kDa centrifugal filters (Millipore). The filtrate was supplemented with 0.1 mM NAD+, 6 mM NADH, 1 μM Cps2N, 1 μM Cps2M, and 1 μM Cps2O in a final volume of 350 μl. The reaction mixture was incubated for 30 min at 37°C, the proteins were removed by filtration, and dTDP-Rha was separated by high-performance liquid chromatography (HPLC) as previously described (25).
Glycosyltransferase assays.
Glycosyltransferase assays to assess the functions of Cps2F, Cps2G, and Cps2I utilized recombinant enzymes expressed separately in E. coli. For each enzyme, membranes containing 3 μg of total protein were incubated for 1 h at 10°C in reaction mixtures containing 10 mM MnCl2, 1 mM DTT, 0.008% NP-40 (in experiments utilizing multiple glycosyltransferases), 0.075 μCi of UDP-[14C]Glc (300 mCi/mmol), and, where indicated, 0.1 mM dTDP-Rha and/or 0.1 mM UDP-GlcUA. The final volume was brought to 75 μl with Tris-acetate (100 mM, pH 7.6). Reactions were stopped with 1 ml of 2:1 chloroform-methanol, and the organic phase was extracted three times with pure solvent upper phase (PSUP; 1.5 ml of chloroform, 25 ml of methanol, 23.5 ml of H2O, and 0.183 g of KCl). Glycolipids were either preserved for later use as described for Und-P-P-14C-Glc-Rha-Rha-Rha (see below) or subjected to mild-acid hydrolysis by suspending the dried organic phase in 80 μl of 20 mM HCl and incubating it at 70°C for 20 min. Hydrolyzed samples were dried, suspended in 10 μl of chloroform-methanol (1:1), and applied as spots on silica-coated thin-layer chromatography (TLC; Whatman) plates. TLC plates were chromatographed for 8 h in butanol-ethanol-water (5:3:2). Dried plates were exposed to a phosphor screen (General Electric Healthcare) for 15 h, and bands were visualized in a Storm 820 phosphorimager (General Electric Healthcare).
Assays to quantify Cps2E activities of the parent and mutant proteins were performed as previously described (24). Except as noted, S. pneumoniae or E. coli membranes containing the indicated amounts of total protein (see figure legends) were incubated for 1 h at 10°C in 75-μl reaction volumes containing 10 mM MnCl2, 1 mM DTT, and 0.075 μCi of UDP-[3H]Glc (43.8 Ci/mmol) in Tris-acetate (100 mM, pH 7.6). The reaction was stopped, and glycolipids were extracted and dried as described above for assays involving E. coli membranes. Incorporated [3H]Glc was analyzed by liquid scintillation counting.
Synthesis of Und-P-P-[14C]Glc-Rha-Rha-Rha (Cps2F product) and assay of Cps2G activity in the absence of other glycosyltransferases.
Reaction mixtures of membranes containing Cps2E, Cps2T, and Cps2F were incubated as described above to synthesize the Cps2F product. Extracted glycolipids were pooled, dried, and suspended in 100 μl of Tris-acetate (100 mM; pH 7.6) containing 0.1% NP-40. This solution was used as the source of Und-P-P-[14C]Glc-Rha-Rha-Rha in subsequent glycosyltransferase reactions. Membranes (3 μg of total protein) from DJ011 containing Cps2G or from RC124, a vector-only E. coli strain, were incubated in reaction mixtures containing 0.008% NP-40, 10 mM MnCl2, 1 mM DTT, 25 μl of the Und-P-P-[14C]Glc-Rha-Rha-Rha solution, and 0.1 mM UDP-Glc. Reaction products were visualized as described above.
Bioinformatic analysis of the Cps2E homologues in S. pneumoniae and other bacteria.
Amino acid sequences from 94 serotypes (90 listed in reference 15 and the remaining 4 in references 45 and 46) were analyzed for Cps2E homologues, which occur in 69 serotypes. These amino acid sequences were aligned by ClustalW (Geneious, version 5.6.4), and a consensus amino acid sequence was generated. Using Fisher's exact test, a significant correlation (P < 0.01) was observed between amino acids that are 100% conserved among S. pneumoniae Cps2E homologues and those selected as suppressor mutations. A protein basic local alignment search tool (BLAST [http://blast.ncbi.nlm.nih.gov/]) was used to identify Cps2E homologues in other bacteria. Homologous proteins from Clostridium phytofermentans ISDg (GenBank accession number YP_001558318), Clostridium bolteae (WP_002576468), Streptococcus oralis (BAD22619), Streptococcus mitis (WP_001013652), and Streptococcus parasanguinis (WP_003009077) were among those identified. Amino acid sequences from these homologues, together with WbaP from Salmonella enterica (YP_008266333) were aligned by ClustalW as described above.
RESULTS AND DISCUSSION
Functional analyses of glycosyltransferases encoded in the cps2 locus.
We previously reported that Cps2E and Cps2T catalyze the first and second steps, respectively, in type 2 CPS synthesis (24, 25). In addition to these enzymes, the cps2 locus encodes three additional predicted glycosyltransferases (Cps2F, Cps2G, and Cps2I) that are expected to catalyze the remaining four glycosidic linkages that complete the capsule repeat unit. The observation that three enzymes might catalyze four linkages suggested that a single glycosyltransferase encoded within the cps locus is capable of adding two sugar residues. We therefore sought to demonstrate the enzyme activities of Cps2F, Cps2G, and Cps2I and also clarify the functions of the gene products whose deletions select for secondary mutations in cps2E (25).
In in vitro glycosyltransferase assays, we utilized individual membrane preparations obtained from E. coli expressing S. pneumoniae glycosyltransferase Cps2F, Cps2G, or Cps2I. The absence of functionally equivalent enzymes in E. coli was demonstrated by the lack of activity when using E. coli membranes from a strain containing only the plasmid vector, as described in the sections below. As previously reported (25), each of the S. pneumoniae glycosyltransferases is membrane associated when expressed in E. coli despite lacking membrane-spanning domains. As for Cps2T (25), in vitro enzyme activity required the addition of nonionic detergent (0.008% NP-40) at a concentration well below the critical micelle concentration. This requirement may reflect a need for temporal disassociation of enzymes from the membrane and access to membrane-bound glycolipid acceptors, possibly as part of the same micelle.
(i) Cps2F.
To identify the enzyme that catalyzes the third step in CPS synthesis, i.e., the second rhamnosyltransferase, we combined Cps2E-containing membranes in reactions with membranes containing Cps2T, nucleotide sugar substrates, and membranes containing the remaining glycosyltransferases. Glycolipids formed in these reactions were extracted and the saccharide moiety was liberated by mild-acid hydrolysis and then separated by TLC. In the presence of UDP-[14C]Glc and dTDP-Rha, only the reaction mixture that contained Cps2F resulted in the formation of a new [14C]Glc-labeled product (Fig. 2), indicating that Cps2F catalyzes the third step in CPS synthesis. The Cps2F-dependent product was consistently generated in several independent reactions (data not shown).
The serotype 2 capsule has two identical inverting linkages (Rha-α-1,3-Rha-α-1,3) (22) (Fig. 1); however, Aanensen et al. identified only one gene (cps2F, also annotated as wchG) in the cps locus that was predicted to encode an inverting transferase (36). This observation suggests that Cps2F may add both Rha residues. Using our standard TLC separation system, we were unable to distinguish two new products (Fig. 2). Alterations in the method, including adjustments to the polarity of the mobile phase, length of run, silica matrix composition, and separation in 2 dimensions, did not greatly increase the separation of the Cps2F and Cps2T products or allow for resolution of a second Cps2F-dependent product (data not shown). Rapid addition of two sugars by Cps2F may not permit distinction of two separate products, and subsequent data demonstrating Cps2G activity (described below) provided evidence for a Cps2F-dependent addition of two consecutive α1-3 Rha residues.
(ii) Cps2G.
To determine which enzyme catalyzes the next step in CPS synthesis, Cps2E-, Cps2T-, and Cps2F-containing membranes were combined with membranes containing Cps2G or Cps2I and UDP-[14C]Glc and dTDP-Rha. In this case, only reaction mixturess with Cps2G resulted in a new [14C]Glc-labeled product (Fig. 3A), indicating that Cps2G activity follows Cps2F activity. Since both UDP-[14C]Glc and dTDP-Rha were added to the reaction mixture, we next sought to identify the sugar specificity of Cps2G. Here, reaction mixtures with membranes containing Cps2E, Cps2T, and Cps2F were used to synthesize the Cps2F lipid-linked reaction product, which was then extracted and incubated with UDP-Glc or dTDP-Rha, and membranes with or without Cps2G. As shown in Fig. 3B, Cps2G was capable of adding Glc, but not Rha, to the Cps2F product, indicating that Cps2G is the α1-2 glucosyltransferase. Although we have not determined the identities of the products formed in these reactions through other biochemical or structural means, these results provide strong evidence for the identity of the Cps2F reaction product as Und-P-P-Glc-Rha-Rha-Rha and indicate that Cps2F sequentially adds two Rha-α-1,3 residues, followed by the addition of Glc by Cps2G.
A mechanism for sequential addition of multiple sugars by a bacterial glycosyltransferase has been reported for PglH from Campylobacter jejuni, which adds three α1-4 N-acetylgalactosamine (GalNAc) residues (47). For PglH, an initial processive synthesis is followed by a dissociative mechanism as products accumulate. Limitation to only three sugar additions is proposed to result from increased binding affinity of products with increasing size, as well as an inability of larger products to move through the active site of the enzyme. PglH contains five copies of the nine-amino-acid motif EX7E, but only one of these was critical for sequential addition of GalNAc residues, suggesting the presence of a single active site (47). The EX7E motif is common among glycosyltransferases (48). It may be essential for activity, as in PglH, or important but not essential, as in PelF from Pseudomonas aeruginosa (49). Similarly, the presence of multiple EX7E motifs could be indicative of a multidomain enzyme with more than one active site, as for enzymes in the E. coli O8 and O9a polymannose O-polysaccharide biosynthetic pathways (50). The EX7E motif occurs once in Cps2F (E100/E108) and several times in other glycosyltransferases of the type 2 pathway (Cps2E, 5 sites; Cps2T, 3 sites; Cps2G, 2 sites; and Cps2I, 2 sites). If this motif is essential for Cps2F activity, the presence of only one EX7E would suggest a single active site for the enzyme. Determination of the importance of the EX7E motif, the number of active sites, and whether control of the number of Rha residues added occurs by a PglH-like counting mechanism awaits further mutational and biochemical studies.
(iii) Cps2I.
To test the ability of Cps2I to add GlcUA, the final sugar of the repeat unit, we used reactions with Cps2E-, Cps2T-, Cps2F-, Cps2G-containing membranes and the nucleotide sugars UDP-[14C]Glc, dTDP-Rha, and UDP-GlcUA. Several attempts, with up to 20 μg of total membrane protein, resulted in no new [14C]Glc-labeled product (Fig. 4 and data not shown). We also tested Cps2I activity directly by measuring the transfer of [14C]GlcUA from UDP-[14C]GlcUA to the Cps2G reaction product. In this case, we combined Cps2E-, Cps2T-, Cps2F-, Cps2G-, and Cps2I-containing membranes with UDP-Glc, dTDP-Rha, and UDP-[14C]GlcUA. Glycolipids formed in these reactions were extracted, dried, and analyzed for the incorporation of [14C]GlcUA. Membranes containing Cps2I did not incorporate [14C]GlcUA above the negative control (identical reactions replacing Cps2I membranes with control membranes). This result was in contrast to the positive control, which demonstrated [14C]GlcUA incorporation by S. pneumoniae membranes containing the serotype 3 synthase Cps3S (data not shown). This enzyme catalyzes the addition of alternating Glc and GlcUA residues from the respective UDP sugars in the synthesis of the serotype 3 capsular polysaccharide (43, 51).
The inability to detect a Cps2I product was not due to reduced amounts of this protein in relation to the other glycosyltransferases in the recombinant membranes, as we previously demonstrated that all of the glycosyltransferases are present at similar levels (25). We also analyzed the effect of the addition of UDP-Glc and E. coli cell lysates containing functional Cps2K to the reactions using independent Cps2E-, Cps2T-, Cps2F-, Cps2G-, and Cps2I-containing membranes. Cps2K is the UDP-Glc dehydrogenase necessary for synthesis of the Cps2I substrate UDP-GlcUA. These additions also did not result in detection of a Cps2I-dependent product (data not shown).
Similar to our result, others have been unable to observe the addition of terminal sugars on membrane-linked polysaccharides from E. coli (GlcUA) and Klebsiella aerogenes (GlcUA) using in vitro assays with membrane-associated glycosyltransferases (52, 53). These results were attributed to limitations of the in vitro systems. Factors that may be important in these systems include possible protein modifications or the requirement for a chaperone. An analysis of the S. pneumoniae phosphoproteome has identified a serine-threonine phosphorylated peptide that corresponds to Cps2I (54), suggesting that modification may be important in Cps2I function.
With only one enzyme and one linkage unaccounted for, we conclude that Cps2I adds the terminal α1-6 GlcUA sugar to the type 2 repeat unit. Support for such a prediction comes from bioinformatic analyses, where cps2I is predicted to encode a retaining glycosyltransferase (36), and α1-6 GlcUA is a retaining linkage.
Suppressor mutations in the extracytoplasmic loop reduce Cps2E activity and CPS levels.
Deletions of the genes encoding glycosyltransferases (Cps2F, Cps2G, or Cps2I), the UDP-glucose dehydrogenase (Cps2K), the Wzx translocase (Cps2J), or the Wzy polymerase (Cps2H) select for isolates carrying secondary mutations, suggesting that the primary mutations are lethal in the absence of suppression (25, 34). Most of these secondary mutations (32 of 35) map to cps2E and are missense mutations (24 of 32) that occur in both the extracytoplasmic and cytoplasmic regions (25, 34) (Fig. 5A). Suppressor mutations in the cytoplasmic loop likely directly inhibit Cps2E Glc-1-P transferase activity, but the specific effects of suppressor mutations in the extracytoplasmic loop, as well as the function of this region, are less evident. Six strains from our collection contain different missense mutations that map to the Cps2E extracytoplasmic loop (Table 1 and Fig. 5A). Each of these mutations results in a nonconservative amino acid change affecting either residue polarity or the presence of an aromatic side chain. No capsule is detectable with either of the S. pneumoniae strains DJ916 (suppressor mutation H258R) and BX552 (L200F), whose primary mutations (Δcps2F and Δcps2H, respectively) eliminate the ability to synthesize the repeating capsule backbone and polymerize the repeat units, respectively (25, 34). However, the Δcps2K mutants (BX547 [D167Y], BX605 [V196G], and BX612 [V165G]) and the Δcps2G mutant (DJ921 [A162S]), each of which lacks the resulting side chain in the polymerized polymer, can synthesize high-molecular-weight polymer, albeit at very low levels. This CPS is detectable only in the membrane, perhaps because of the higher fraction of polysaccharide normally located there (25, 34). Because high levels of membrane-associated polysaccharide can accumulate in the parent without harm, we have interpreted this result to be indicative of the ability to transfer CPS from Und-P not only to peptidoglycan but also to another membrane acceptor in the parent, allowing the Und-P to be recycled (34). The low level of CPS produced by the Δcps2K and Δcps2G mutants may reflect a reduced ability to make this transfer, with the cps2E mutations resulting in less functional enzymes that slow synthesis of repeat units, thereby allowing the transfer to keep pace. The reduced transfer from Und-P could occur because of altered recognition of the incomplete repeat unit by one or more enzymes in the pathway (i.e., the Wzx transporter, the Wzy polymerase, or the as-yet-unknown enzyme that moves the polymer to it final destination).
To test the effects of the extracytoplasmic loop mutations on Cps2E activity, we used the strains described above in in vitro glycosyltransferase assays. Each of the mutants exhibited activity barely above that observed for the Cps2E-negative control strain (Fig. 6A, mutations H258R, A162S, D167Y, L200F, and V196G). This result was similar to what we observed previously for Δcps2K mutants that contained mutations in the Cps2E cytoplasmic loop (34). We again tested the latter effect using recently isolated Δcps2G mutants containing mutations in the Cps2E cytoplasmic loop (25). Again, minimal activity was observed (M338I and R307S in Fig. 6A). In immunoblots of Cps2E, we noted reduced levels of protein for most of the extracytoplasmic loop mutants, but no reduction was evident for the cytoplasmic mutants in either this or the previous study (Fig. 6B and reference 34). The reduction in protein levels alone should not be sufficient to account for the severe reductions in Cps2E activity, indicating that other effects may be involved.
To address the possibility that Cps2E activities for the extracytoplasmic loop mutants might be reduced as a result of the primary deletion mutations, we introduced two of the mutations (H258R, derived from the Δcps2F strain DJ916, and V196G, derived from the Δcps2K strain BX605) into the parent, D39. Using membranes from these mutants, we were unable to detect Cps2E activity, even with increased amounts of membranes (Fig. 7A). As in the original deletion strains, the H258R mutant exhibited Cps2E protein levels similar to those of the parent, whereas the V196G mutant was reduced (Fig. 7B). In contrast, the non-capsule-related protein PspA, which fractionates with the membranes (44), was present in similar amounts in the parent and mutant strains (Fig. 7B). By the Quellung reaction, which uses reactivity with antiserum for microscopic observation of CPS, the mutants appeared to be CPS negative (data not shown). In the more sensitive immunoblot assay used to detect CPS in membrane and cell wall fractions, however, CPS was evident and displayed the full range of low- to high-molecular-weight polymers, albeit at reduced amounts (Fig. 7C). The amount of CPS produced was greater than that seen for the original strains containing both a cps2E mutation and a deletion (25), an effect we observed previously with mutations in the cytoplasmic loop (34).
To further test the effect of the extracytoplasmic loop mutations on Cps2E activity, we expressed each of the mutant proteins in E. coli. In this case, other S. pneumoniae proteins that might repress activity, possibly through enhanced interactions with the mutant Cps2E proteins, would be eliminated. Once again, we were unable to detect activity (Fig. 8A). Similar to the results in S. pneumoniae, three of the mutant proteins (D167Y, L200F, and V196G) were detected at lower levels in the membranes than was parental Cps2E (Fig. 8B).
Two observations from this series of experiments merit further consideration. First, the production of more CPS by mutants containing only a suppressor mutation in cps2E, as opposed to both a suppressor mutation and the original deletion mutation, suggests that the low CPS levels in the latter strains are not due solely to reduced Cps2E activity. This observation could suggest a feedback type of regulation, where Cps2E activity is normally reduced when the end products (partial or complete repeat units) accumulate. The normal feedback inhibition may not be sufficient in the deletion mutants where excessive amounts of end products accumulate, thus necessitating suppressor mutations for survival. In the mutants containing only the cps2E mutations, the feedback inhibition is relieved (returned to normal levels), and CPS amounts reflect the effects of only the cps2E mutations. Second, the reduced levels of Cps2E in many of the mutants suggest that instability may occur as a result of the mutations. While we cannot exclude the possibility of differences in expression levels in the E. coli system, the observation of similar effects in E. coli and in S. pneumoniae isolates with both a deletion and a point mutation or just a point mutation lends credence to this possibility. The reduced levels of Cps2E activity and CPS may result in part from this effect. For many mutants, however, the reductions in Cps2E protein levels are modest in relation to the near complete loss of in vitro glycosyltransferase activity. Further, reduced stability does not explain the observation of similar levels of CPS in mutants that made normal amounts of Cps2E (such as H258R and cytoplasmic loop mutants) and those that make severely reduced levels of Cps2E (other extracytoplamic loop mutants). Perhaps this instability and reduced activity reflect a loss or severe reduction in interaction(s) with protein(s) or other factors that is more extreme in vitro but where interactions in vivo may still be sufficient for some CPS production to occur. The fact that instability occurs with mutations in the extracytoplasmic, but not cytoplasmic, loop suggests that this may be a critical region for interactions. In wild-type bacteria, such interactions may lead to enhanced Cps2E activity and CPS synthesis, but the interactions and activities are reduced by the point mutations. While interacting partners, if they exist, are not yet known, possibilities include the Wzx transporter (flippase), Wzy polymerase, Cps2A, and Cps2C, all of which have extracellular domains. Additional possibilities include the CPS polymer or repeat units and environmental factors.
Amino acids selected for suppressor mutations in Cps2E correlate with highly conserved residues across CpsE homologues in S. pneumoniae and other bacteria.
Cps2E homologues are present in at least 69 S. pneumoniae serotypes (15, 45, 46). To evaluate whether residues selected as suppressor mutations in Cps2E are conserved in these 69 serotypes, we employed a ClustalW alignment to generate a consensus CpsE amino acid sequence. As indicated in Fig. 5B, 216/455 amino acids are 100% conserved across the 69 S. pneumoniae Cps2E homologues. To date, we have identified 22 unique missense suppressor mutations in cps2E (among 24 total); 17 of these affect amino acids that are 100% conserved in the 69 serotypes (P < 0.01) (Fig. 5B). Nine of the residues are also conserved among multiple other Gram-positive bacteria, including streptococcal and clostridial species (Fig. 5B). Twelve of these residues (A162, D167, G292, G303, K313, F339, P363, G371, E385, G411, D425, and W435) are also conserved in their relative positions in WbaP (A177, D182, G310, G321, K331, F361, P385, G393, E407, G433, D446, and W467), the initiating glycosyltransferase for the S. enterica O antigen. The extracytoplasmic loops for both Cps2E and WbaP are 148 amino acids in length but share limited sequence identity (23/152 residues [15%]; positives = 49/152 [32%]; gaps = 8/152 [5%]). These results indicate that the selection for suppressor mutations in Cps2E identifies important and highly conserved functional residues.
Conclusions.
The assembly of surface polysaccharides requires multiple enzymes in a complex process that is undoubtedly highly coordinated. The results obtained in this and other studies from our laboratory (24, 25, 34) and others (31) continue to suggest that Cps2E and related enzymes play central roles in the regulation of this process. The existence of the extracytoplasmic loop and the effect of mutations therein suggest a function that is necessary for interaction with other surface enzymes, repeat units/polymer, or with an environmental factor.
In S. enterica WbaP mutants in which only the extracytoplasmic loop is lacking, O antigen is produced at levels similar to that of the parent but with an increased frequency of polymers in the 10- to 20-repeat-unit range, and in vitro glycosyltransferase activity is comparable to that of the parent (31). The present results suggest that in addition to any potential role in modulation of chain length, the extracytoplasmic loop may have a role in regulating initiation of capsule synthesis. The cytoplasmic loop alone appears capable of initiating synthesis, however, as one of the extracytoplasmic loop mutations obtained in our original study contained a nonsense mutation (E191*) just prior to a secondary translation start that effectively separated the N- and C-terminal regions. This mutant was able to produce CPS, albeit at low levels (reference 34 and unpublished data). This result is consistent with the observation that the cytoplasmic region and the final transmembrane domain are sufficient for activity in other glycosyltransferases of the PHPT family (27, 31, 32, 35). In the native S. pneumoniae system, however, that activity may not be optimal in the absence of a fully functional outer loop.
The requirement for suppressor mutations when capsule synthesis is blocked at a point past the committed step provides a powerful tool to identify critical residues of Cps2E. Despite the fact that mutations in many other genes (including cps2LMNO [dTDP-Rha synthesis], cps2C and cps2D [tyrosine phosphoregulatory pathway], and cps2T [first rhamnosyltransferase]) could reduce or eliminate CPS synthesis, 32 of 35 suppressor mutations have thus far occurred in cp2E. These results suggest that there are a greater number of effective target sites in cps2E than in all other sites combined, even though the collective target size for the genes above is more than 4 times that of cps2E. We have not yet reached saturation mutagenesis; thus, many other residues likely remain to be identified, providing the potential to better understand the multiple roles of Cps2E and related enzymes in capsule synthesis.
ACKNOWLEDGMENTS
This work was supported by Public Health Service grant AI28457 from the National Institutes of Health and by the Mizutani Foundation for Glycoscience.
We thank Ella Robinson for graphics assistance.
Footnotes
Published ahead of print 4 October 2013
REFERENCES
- 1.Avery OT, Dubos R. 1931. The protective action of a specific enzyme against type III pneumococcus infection in mice. J. Exp. Med. 54:73–89 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Brown EJ, Joiner KA, Cole RM, Berger M. 1983. Localization of complement component 3 on Streptococcus pneumoniae: anti-capsular antibody causes complement deposition on the pneumococcal capsule. Infect. Immun. 39:403–409 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Griffith F. 1928. The significance of Pneumococcal types. J. Hyg. (Lond.) 27:113–159 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Hardy GG, Magee AD, Ventura CL, Caimano MJ, Yother J. 2001. Essential role for cellular phosphoglucomutase in virulence of type 3 Streptococcus pneumoniae. Infect. Immun. 69:2309–2317 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Magee AD, Yother J. 2001. Requirement for capsule in colonization by Streptococcus pneumoniae. Infect. Immun. 69:3755–3761 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Nelson AL, Roche AM, Gould JM, Chim K, Ratner AJ, Weiser JN. 2007. Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance. Infect. Immun. 75:83–90 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Weiser JN, Austrian R, Sreenivasan PK, Masure HR. 1994. Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect. Immun. 62:2582–2589 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Wood WB, Jr, Smith MR. 1949. The inhibition of surface phagocytosis by the capsular slime layer of pneumococcus type III. J. Exp. Med. 90:85–96 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Francis T, Tillett WS. 1930. Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide. J. Exp. Med. 52:573–585 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Macleod CM, Hodges RG, Heidelberger M, Bernhard WG. 1945. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 82:445–465 [PMC free article] [PubMed] [Google Scholar]
- 11.van Dam JE, Fleer A, Snippe H. 1990. Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides. Antonie Van Leeuwenhoek 58:1–47 [DOI] [PubMed] [Google Scholar]
- 12.Centers for Disease Control and Prevention 2011. Epidemiology and prevention of vaccine-preventable diseases, 12th ed, p 233–248 Public Health Foundation, Washington, DC [Google Scholar]
- 13.Weiser J, Nahm MH. 2008. Immunity to extracellular bacteria, p 1182–1203 In Paul WE. (ed), Fundamental immunology, 6th ed. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA [Google Scholar]
- 14.Abramson JS, Baker CJ, Fisher MC, Gerber MA, Meissner HC, Murray DL, Overturf GD, Prober CG, Rennels MB, Saari TN, Weiner LB, Whitley RJ. 2000. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 106:362–366 [DOI] [PubMed] [Google Scholar]
- 15.Bentley SD, Aanensen DM, Mavroidi A, Saunders D, Rabbinowitsch E, Collins M, Donohoe K, Harris D, Murphy L, Quail MA, Samuel G, Skovsted IC, Kaltoft MS, Barrell B, Reeves PR, Parkhill J, Spratt BG. 2006. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet. 2:e31. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Dillard JP, Vandersea MW, Yother J. 1995. Characterization of the cassette containing genes for type 3 capsular polysaccharide biosynthesis in Streptococcus pneumoniae. J. Exp. Med. 181:973–983 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Llull D, Garcia E, Lopez R. 2001. Tts, a processive beta-glucosyltransferase of Streptococcus pneumoniae, directs the synthesis of the branched type 37 capsular polysaccharide in pneumococcus and other gram-positive species. J. Biol. Chem. 276:21053–21061 [DOI] [PubMed] [Google Scholar]
- 18.Yother J. 2011. Capsules of Streptococcus pneumoniae and other bacteria: paradigms for polysaccharide biosynthesis and regulation. Annu. Rev. Microbiol. 65:563–581 [DOI] [PubMed] [Google Scholar]
- 19.Raetz CR, Whitfield C. 2002. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71:635–700 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Valvano MA. 2003. Export of O-specific lipopolysaccharide. Front. Biosci. 8:s452–s471 [DOI] [PubMed] [Google Scholar]
- 21.Whitfield C. 2006. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu. Rev. Biochem. 75:39–68 [DOI] [PubMed] [Google Scholar]
- 22.Jansson PE, Lindberg B, Anderson M, Lindquist U, Henrichsen J. 1988. Structural studies of the capsular polysaccharide from Streptococcus pneumoniae type 2, a reinvestigation. Carbohydr. Res. 182:111–117 [DOI] [PubMed] [Google Scholar]
- 23.Yother J, Bentley SD, Hennessey JP. 2008. Genetics, biosynthesis, and chemistry of pneumococcal capsular polysaccharides, p 33–46 In Siber GR, Klugman KP, Makela PH. (ed), Pneumococcal vaccines: the impact of conjugate vaccine. ASM Press, Washington, DC [Google Scholar]
- 24.Cartee RT, Forsee WT, Bender MH, Ambrose KD, Yother J. 2005. CpsE from type 2 Streptococcus pneumoniae catalyzes the reversible addition of glucose-1-phosphate to a polyprenyl phosphate acceptor, initiating type 2 capsule repeat unit formation. J. Bacteriol. 187:7425–7433 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.James DBA, Yother J. 2012. Genetic and biochemical characterizations of enzymes involved in Streptococcus pneumoniae serotype 2 capsule synthesis demonstrate that Cps2T (WchF) catalyzes the committed step by addition of beta1-4 rhamnose, the second sugar residue in the repeat unit. J. Bacteriol. 194:6479–6489 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Kolkman MA, Morrison DA, Van Der Zeijst BA, Nuijten PJ. 1996. The capsule polysaccharide synthesis locus of Streptococcus pneumoniae serotype 14: identification of the glycosyl transferase gene cps14E. J. Bacteriol. 178:3736–3741 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Pelosi L, Boumedienne M, Saksouk N, Geiselmann J, Geremia RA. 2005. The glucosyl-1-phosphate transferase WchA (Cap8E) primes the capsular polysaccharide repeat unit biosynthesis of Streptococcus pneumoniae serotype 8. Biochem. Biophys. Res. Commun. 327:857–865 [DOI] [PubMed] [Google Scholar]
- 28.van Selm S, Kolkman MA, van der Zeijst BA, Zwaagstra KA, Gaastra W, van Putten JP. 2002. Organization and characterization of the capsule biosynthesis locus of Streptococcus pneumoniae serotype 9V. Microbiology 148:1747–1755 [DOI] [PubMed] [Google Scholar]
- 29.Jiang XM, Neal B, Santiago F, Lee SJ, Romana LK, Reeves PR. 1991. Structure and sequence of the rfb (O antigen) gene cluster of Salmonella serovar typhimurium (strain LT2). Mol. Microbiol. 5:695–713 [DOI] [PubMed] [Google Scholar]
- 30.Yuasa R, Levinthal M, Nikaido H. 1969. Biosynthesis of cell wall lipopolysaccharide in mutants of Salmonella. V. A mutant of Salmonella typhimurium defective in the synthesis of cytidine diphosphoabequose. J. Bacteriol. 100:433–444 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Saldias MS, Patel K, Marolda CL, Bittner M, Contreras I, Valvano MA. 2008. Distinct functional domains of the Salmonella enterica WbaP transferase that is involved in the initiation reaction for synthesis of the O antigen subunit. Microbiology 154:440–453 [DOI] [PubMed] [Google Scholar]
- 32.Wang L, Liu D, Reeves PR. 1996. C-terminal half of Salmonella enterica WbaP (RfbP) is the galactosyl-1-phosphate transferase domain catalyzing the first step of O-antigen synthesis. J. Bacteriol. 178:2598–2604 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Wang L, Reeves PR. 1994. Involvement of the galactosyl-1-phosphate transferase encoded by the Salmonella enterica rfbP gene in O-antigen subunit processing. J. Bacteriol. 176:4348–4356 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Xayarath B, Yother J. 2007. Mutations blocking side chain assembly, polymerization, or transport of a Wzy-dependent Streptococcus pneumoniae capsule are lethal in the absence of suppressor mutations and can affect polymer transfer to the cell wall. J. Bacteriol. 189:3369–3381 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Patel KB, Ciepichal E, Swiezewska E, Valvano MA. 2011. The C-terminal domain of the Salmonella enterica WbaP (UDP-galactose:Und-P galactose-1-phosphate transferase) is sufficient for catalytic activity and specificity for undecaprenyl monophosphate. Glycobiology 22:116–122 [DOI] [PubMed] [Google Scholar]
- 36.Aanensen DM, Mavroidi A, Bentley SD, Reeves PR, Spratt BG. 2007. Predicted functions and linkage specificities of the products of the Streptococcus pneumoniae capsular biosynthetic loci. J. Bacteriol. 189:7856–7876 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Iannelli F, Pearce BJ, Pozzi G. 1999. The type 2 capsule locus of Streptococcus pneumoniae. J. Bacteriol. 181:2652–2654 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Burrows LL, Lam JS. 1999. Effect of wzx (rfbX) mutations on A-band and B-band lipopolysaccharide biosynthesis in Pseudomonas aeruginosa O5. J. Bacteriol. 181:973–980 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Katzen F, Ferreiro DU, Oddo CG, Ielmini MV, Becker A, Puhler A, Ielpi L. 1998. Xanthomonas campestris pv. campestris gum mutants: effects on xanthan biosynthesis and plant virulence. J. Bacteriol. 180:1607–1617 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Tao L, LeBlanc DJ, Ferretti JJ. 1992. Novel streptococcal-integration shuttle vectors for gene cloning and inactivation. Gene 120:105–110 [DOI] [PubMed] [Google Scholar]
- 41.Yother J, Handsome GL, Briles DE. 1992. Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J. Bacteriol. 174:610–618 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Hardy GG, Caimano MJ, Yother J. 2000. Capsule biosynthesis and basic metabolism in Streptococcus pneumoniae are linked through the cellular phosphoglucomutase. J. Bacteriol. 182:1854–1863 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Cartee RT, Forsee WT, Schutzbach JS, Yother J. 2000. Mechanism of type 3 capsular polysaccharide synthesis in Streptococcus pneumoniae. J. Biol. Chem. 275:3907–3914 [DOI] [PubMed] [Google Scholar]
- 44.Yother J, White JM. 1994. Novel surface attachment mechanism of the Streptococcus pneumoniae protein PspA. J. Bacteriol. 176:2976–2985 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Calix JJ, Nahm MH. 2010. A new pneumococcal serotype, 11E, has a variably inactivated wcjE gene. J. Infect. Dis. 202:29–38 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Calix JJ, Porambo RJ, Brady AM, Larson TR, Yother J, Abeygunwardana C, Nahm MH. 2012. Biochemical, genetic, and serological characterization of two capsule subtypes among Streptococcus pneumoniae serotype 20 strains: discovery of a new pneumococcal serotype. J. Biol. Chem. 287:27885–27894 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Troutman JM, Imperiali B. 2009. Campylobacter jejuni PglH is a single active site processive polymerase that utilizes product inhibition to limit sequential glycosyl transfer reactions. Biochemistry 48:2807–2816 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Coutinho PM, Deleury E, Davies GJ, Henrissat B. 2003. An evolving hierarchical family classification for glycosyltransferases. J. Mol. Biol. 328:307–317 [DOI] [PubMed] [Google Scholar]
- 49.Ghafoor A, Jordens Z, Rehm BH. 2013. Role of PelF in pel polysaccharide biosynthesis in Pseudomonas aeruginosa. Appl. Environ. Microbiol. 79:2968–2978 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Greenfield LK, Richards MR, Li J, Wakarchuk WW, Lowary TL, Whitfield C. 2012. Biosynthesis of the polymannose lipopolysaccharide O-antigens from Escherichia coli serotypes O8 and O9a requires a unique combination of single- and multiple-active site mannosyltransferases. J. Biol. Chem. 287:35078–35091 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Dillard JP, Yother J. 1994. Genetic and molecular characterization of capsular polysaccharide biosynthesis in Streptococcus pneumoniae type 3. Mol. Microbiol. 12:959–972 [DOI] [PubMed] [Google Scholar]
- 52.Drummelsmith J, Whitfield C. 1999. Gene products required for surface expression of the capsular form of the group 1 K antigen in Escherichia coli (O9a:K30). Mol. Microbiol. 31:1321–1332 [DOI] [PubMed] [Google Scholar]
- 53.Sutherland IW, Norval M. 1970. The synthesis of exopolysaccharide by Klebsiella aerogenes membrane preparations and the involvement of lipid intermediates. Biochem. J. 120:567–576 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Sun X, Ge F, Xiao CL, Yin XF, Ge R, Zhang LH, He QY. 2010. Phosphoproteomic analysis reveals the multiple roles of phosphorylation in pathogenic bacterium Streptococcus pneumoniae. J. Proteome Res. 9:275–282 [DOI] [PubMed] [Google Scholar]
- 55.Yother J. 2006. Integration of capsular polysaccharide biosynthesis with metabolic and virulence pathways in Streptococcus pneumoniae, p 51–65 In Brogden KA, Minion FC, Cornick N, Stanton TB, Zhang Q, Nolan LK, Wannemuehler MJ. (ed), Virulence mechanisms of bacterial pathogens, 4th ed. ASM Press, Washington, DC [Google Scholar]
- 56.Bender MH, Cartee RT, Yother J. 2003. Positive correlation between tyrosine phosphorylation of CpsD and capsular polysaccharide production in Streptococcus pneumoniae. J. Bacteriol. 185:6057–6066 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Avery OT, MacLeod CM, McCarty M. 1944. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a deoxyribonucleic acid fraction isolated from pneumococcus type III. J. Exp. Med. 79:137–158 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Briles DE, Nahm M, Schroer K, Davie J, Baker P, Kearney J, Barletta R. 1981. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J. Exp. Med. 153:694–705 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Macrina FL, Tobian JA, Jones KR, Evans RP, Clewell DB. 1982. A cloning vector able to replicate in Escherichia coli and Streptococcus sanguis. Gene 19:345–353 [DOI] [PubMed] [Google Scholar]